The Valve Track Has Multiple Layouts, and the R&D Innovation Heat is Rising

Cardiac valve disease refers to impairment of cardiac function caused by changes in the anatomy and/or function of the heart valves, characterized by one or more of the four heart valves (i.e., aortic, mitral, tricuspid, and pulmonary) damage or defect occurs.

                              Growth of patients with mitral regurgitation in China from 2015 to 2025

Heart valve disease has a large demand for treatment, and its treatment field has great potential for development in the industry. Among them, mitral valve and tricuspid valve interventional therapy is a hot track for artificial heart valve research and development companies in recent years.

Our country's artificial heart valve industry is at the starting point of development. With the concerted efforts of industry, academia, research and other circles, it will continue to break through the technical barriers of the industry and continue to develop towards intelligence, precision and minimally invasiveness.

Growth of patients with tricuspid regurgitation in China from 2015 to 2025

Market demand continues to grow

Mitral regurgitation is the most common heart valve disease. According to the data, the number of patients with moderate to severe mitral regurgitation in my country has increased from 9.8 million in 2016 to 10.8 million in 2020, with a compound annual growth rate from 2016 to 2020;

And the prevalence is expected to reach 12.1 million in 2025 and 13.2 million in 2030, with a projected CAGR of 2.3% from 2020 to 2025, and 2025 to 2030 The compound annual growth rate will reach 1.8% (see Figure 1 for details).

According to Frost & Sullivan, a global business growth consulting firm, the global mitral valve intervention market will reach US$17.4 billion in 2030.

Global companies have deployed

Heart valve interventional therapy has always been a popular track in the field of cardiovascular and even medical devices.

At present, the powerful companies in this field in the domestic market can be divided into three categories: one is the global medical device giants represented by Abbott, Edward Life Sciences, etc.; the second is domestic listed companies, such as MicroPort® Xintong, Qiming Medical, Peijia Medical; the third category is local start-ups focusing on the mitral valve field, such as Hanyu Medical, New Pulse Medical, etc.

Since our country's artificial heart valve industry is still in its infancy, and the global mitral valve and tricuspid valve interventional treatment field still has a large number of sub-field clinical needs that have not been met, domestic companies are expected to rely on key technological breakthroughs to continuously develop a broad global market.